AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

ONCOSIL MEDICAL LTD

0.725

+0.0050.69%

Volume:256.00

Turnover:184.00

Market Cap:17.12M

PE:-0.52

High:0.725

Open:0.720

Low:0.720

Close:0.720

52wk High:2.800

52wk Low:0.660

Shares:23.62M

Float Shares:16.80M

Volume Ratio:0.00

T/O Rate:0.00%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.382

EPS(LYR):-1.382

ROE:-385.20%

ROA:-136.02%

PB:5.52

PE(LYR):-0.52

Loading ...

Overview Company News Filings

Oncosil Medical Ltd-Resignation of Joint Company Secretary

THOMSON REUTERS

BRIEF-Oncosil Medical Announces A$8.0 Million Capital Raise At A$0.68/ Share

Oncosil Medical - a$8.0 Mln Capital Raise at a$0.68 per New Share

THOMSON REUTERS

BRIEF-Oncosil Medical Seeks Trading Halt

Oncosil Medical Ltd - Trading Halt Pending Capital Raising Announcement

THOMSON REUTERS

Oncosil Medical Ltd-Retirement of Non-Executive Director

THOMSON REUTERS

Oncosil Medical Ltd-Response to ASX Query Letter

THOMSON REUTERS

OncoSil Medical Reports First Pancreatic Cancer Device Treatment in Germany

MT Newswires Live

OncoSil Medical Begins Commercial Operations in Portugal with First Patient Treatment

MT Newswires Live

OncoSil Medical Receives Positive Preliminary Results From Investigator-Initiated Pancreatic Cancer Study; Shares Up 14%

MT Newswires Live

Oncosil Medical Ltd - Trading Halt Requested Pending Pancosil Trial Results

THOMSON REUTERS

BRIEF-Oncosil Medical Appoints Thomas Duthy As Non-Executive Chairman

OncoSil Medical Promotes Thomas Duthy to Non-Executive Chairman; Shares Jump 13%

MT Newswires Live

Oncosil Medical Ltd - Appoints Thomas Duthy as Non-Executive Chairman

THOMSON REUTERS

BRIEF-Oncosil Medical Reports FY Loss Attributable A$15.1 Million

Oncosil Medical Ltd - FY Revenues From Ordinary Activities a$1.2 Mln

THOMSON REUTERS

Oncosil Medical - FY Loss Attributable a$15.1 Million

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/OSL.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"OSL.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"OSL.AU\",,,,,undefined,":{"symbol":"OSL.AU","market":"AU","secType":"STK","nameCN":"ONCOSIL MEDICAL LTD","latestPrice":0.725,"timestamp":1770778160555,"preClose":0.72,"halted":0,"volume":256,"delay":0,"changeRate":0.006944444444444451,"nameEN":"ONCOSIL MEDICAL LTD","floatShares":16797755,"shares":23615334,"eps":-1.381715,"marketStatus":"Trading","change":0.005,"latestTime":"02-11 14:02:21 AEDT","open":0.72,"high":0.725,"low":0.72,"amount":184,"amplitude":0.006944,"askPrice":0.775,"askSize":14920,"bidPrice":0.725,"bidSize":1451,"shortable":3,"etf":0,"ttmEps":-1.381715,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1770786000000},"marketStatusCode":2,"adr":0,"exchange":"ASX","adjPreClose":0.72,"openAndCloseTimeList":[[1770764400000,1770786000000]],"volumeRatio":0.002022,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"OSL.AU\",,,,,undefined,":{"symbol":"OSL.AU","floatShares":16797755,"roa":"-136.02%","roe":"-385.20%","lyrEps":-1.381715,"volumeRatio":0.002022,"shares":23615334,"dividePrice":0,"high":0.725,"amplitude":0.006944,"preClose":0.72,"low":0.72,"week52Low":0.66,"pbRate":"5.52","psRate":"11.15","week52High":2.8,"institutionHeld":0,"latestPrice":0.725,"committee":-0.822735,"eps":-1.381715,"divideRate":0,"volume":256,"delay":0,"ttmEps":-1.381715,"open":0.72,"prevYearClose":0.97,"prevWeekClose":0.68,"prevMonthClose":0.8,"prevQuarterClose":0.97,"fiveDayClose":0.71,"twentyDayClose":0.86,"sixtyDayClose":1.31,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/OSL.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2025-06-03","symbol":"OSL.AU","defaultRemindTime":1748908800000,"type":"split","dateTimestamp":1748872800000,"forFactor":400,"toFactor":1,"ratio":400},{"market":"AU","date":"2022-05-05","symbol":"OSL.AU","defaultRemindTime":1651708800000,"type":"split","dateTimestamp":1651672800000,"forFactor":987878,"toFactor":1000000,"ratio":0.987878}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"OSL.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"OSL.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2609354319","title":"Oncosil Medical Ltd-Resignation of Joint Company Secretary","url":"https://stock-news.laohu8.com/highlight/detail?id=2609354319","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609354319?lang=en_us&edition=fundamental","pubTime":"2026-02-05 06:07","pubTimestamp":1770242826,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260204:nTUE9YCVPZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7048","BK7508","OSL.AU"],"gpt_icon":0},{"id":"2608140468","title":"BRIEF-Oncosil Medical Announces A$8.0 Million Capital Raise At A$0.68/ Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2608140468","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608140468?lang=en_us&edition=fundamental","pubTime":"2026-02-03 09:16","pubTimestamp":1770081395,"startTime":"0","endTime":"0","summary":"BRIEF-Oncosil Medical Announces A$8.0 Million Capital Raise At A$0.68/ ShareFeb 3 (Reuters) - Oncosil Medical Ltd OSL.AX:A$8.0 MILLION CAPITAL RAISE AT A$0.68 PER NEW SHAREFurther company coverage: OSL.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nFWN3YY102:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OSL.AU","BK7508","BK7048"],"gpt_icon":0},{"id":"2608819827","title":"Oncosil Medical -  a$8.0 Mln Capital Raise at a$0.68 per New Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2608819827","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608819827?lang=en_us&edition=fundamental","pubTime":"2026-02-03 07:53","pubTimestamp":1770076414,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nFWN3YY102:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7048","OSL.AU"],"gpt_icon":0},{"id":"2607068736","title":"BRIEF-Oncosil Medical Seeks Trading Halt","url":"https://stock-news.laohu8.com/highlight/detail?id=2607068736","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607068736?lang=en_us&edition=fundamental","pubTime":"2026-01-30 08:33","pubTimestamp":1769733209,"startTime":"0","endTime":"0","summary":"BRIEF-Oncosil Medical Seeks Trading HaltJan 30 (Reuters) - Oncosil Medical Ltd OSL.AX:TRADING HALT PENDING CAPITAL RAISING ANNOUNCEMENTFurther company coverage: OSL.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260130:nFWN3YU1HS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7048","BK7508","OSL.AU"],"gpt_icon":0},{"id":"2607054118","title":"Oncosil Medical Ltd - Trading Halt Pending Capital Raising Announcement","url":"https://stock-news.laohu8.com/highlight/detail?id=2607054118","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607054118?lang=en_us&edition=fundamental","pubTime":"2026-01-30 06:06","pubTimestamp":1769724405,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260129:nFWN3YU1HS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7048","OSL.AU"],"gpt_icon":0},{"id":"2580231217","title":"Oncosil Medical Ltd-Retirement of Non-Executive Director","url":"https://stock-news.laohu8.com/highlight/detail?id=2580231217","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580231217?lang=en_us&edition=fundamental","pubTime":"2025-11-03 06:23","pubTimestamp":1762122198,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251102:nTUE8RWBX3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7048","OSL.AU"],"gpt_icon":0},{"id":"2578098116","title":"Oncosil Medical Ltd-Response to ASX Query Letter","url":"https://stock-news.laohu8.com/highlight/detail?id=2578098116","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578098116?lang=en_us&edition=fundamental","pubTime":"2025-10-28 14:58","pubTimestamp":1761634694,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251028:nTUE8HJW95:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OSL.AU","BK7508","BK7048"],"gpt_icon":0},{"id":"2575601760","title":"OncoSil Medical Reports First Pancreatic Cancer Device Treatment in Germany","url":"https://stock-news.laohu8.com/highlight/detail?id=2575601760","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575601760?lang=en_us&edition=fundamental","pubTime":"2025-10-16 11:10","pubTimestamp":1760584213,"startTime":"0","endTime":"0","summary":"OncoSil Medical (ASX:OSL) started its commercial rollout in Germany with the first treatment using the OncoSil device at Universitatsklinikum Augsburg on Wednesday, according to a Thursday filing with","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","OSL.AU","BK7048"],"gpt_icon":0},{"id":"2572521266","title":"OncoSil Medical Begins Commercial Operations in Portugal with First Patient Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2572521266","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572521266?lang=en_us&edition=fundamental","pubTime":"2025-10-03 07:35","pubTimestamp":1759448150,"startTime":"0","endTime":"0","summary":"OncoSil Medical  has commenced its commercial rollout in Portugal with the successful first treatment using the OncoSil device at Instituto Portugues de Oncologia do Porto Francisco Gentil on Oct. 2, according to a Friday filing with the Australian bourse.The company will continue partnering with clinicians in Portugal to support OncoSil adoption and expand into new international markets, the filing added.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7048","OSL.AU","BK7508"],"gpt_icon":0},{"id":"2568449281","title":"OncoSil Medical Receives Positive Preliminary Results From Investigator-Initiated Pancreatic Cancer Study; Shares Up 14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2568449281","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568449281?lang=en_us&edition=fundamental","pubTime":"2025-09-18 09:18","pubTimestamp":1758158297,"startTime":"0","endTime":"0","summary":"OncoSil Medical  received positive preliminary results from an investigator-initiated study, indicating that it is \"safe and feasible\" to deliver OncoSil by computerized tomography-guided percutaneous administration, according to a Thursday filing with the Australian bourse.OncoSil is a medical device that delivers a targeted dose of radiation directly into cancerous tissue in locally advanced pancreatic cancer.The procedure had a 90% technical success rate, with 10% of patients experiencing third-grade serious adverse device events, the filing said.The company anticipates securing additional regulatory approvals in the second half of fiscal 2026.Pancosil is a first-in-the-world study administering OncoSil through direct injection through the skin, according to the filing.OncoSil Medical shares rose 14% in morning trade Thursday.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","BK7048","OSL.AU"],"gpt_icon":0},{"id":"2568343143","title":"Oncosil Medical Ltd - Trading Halt Requested Pending Pancosil Trial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2568343143","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568343143?lang=en_us&edition=fundamental","pubTime":"2025-09-17 06:41","pubTimestamp":1758062506,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250916:nFWN3V30IO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7048","OSL.AU"],"gpt_icon":0},{"id":"2566651982","title":"BRIEF-Oncosil Medical Appoints Thomas Duthy As Non-Executive Chairman","url":"https://stock-news.laohu8.com/highlight/detail?id=2566651982","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566651982?lang=en_us&edition=fundamental","pubTime":"2025-09-09 09:32","pubTimestamp":1757381539,"startTime":"0","endTime":"0","summary":"BRIEF-Oncosil Medical Appoints Thomas Duthy As Non-Executive ChairmanSept 9 (Reuters) - Oncosil Medical Ltd OSL.AX:APPOINTS THOMAS DUTHY AS NON-EXECUTIVE CHAIRMANFurther company coverage: OSL.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250909:nFWN3UV179:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","OSL.AU","BK7048"],"gpt_icon":0},{"id":"2566651357","title":"OncoSil Medical Promotes Thomas Duthy to Non-Executive Chairman; Shares Jump 13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2566651357","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566651357?lang=en_us&edition=fundamental","pubTime":"2025-09-09 09:18","pubTimestamp":1757380708,"startTime":"0","endTime":"0","summary":"OncoSil Medical  promoted Non-Executive Director Thomas Duthy to non-executive chairman, effective Oct. 1, according to a Tuesday filing with the Australian bourse.Duthy will succeed current Chairman Doug Cubbin, who will remain in the role temporarily to help facilitate a smooth transition, the filing said.The company's shares surged almost 13% in recent Tuesday trade.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XKO.AU","BK7508","BK7048","XAO.AU","XJO.AU","OSL.AU"],"gpt_icon":0},{"id":"2566536166","title":"Oncosil Medical Ltd - Appoints Thomas Duthy as Non-Executive Chairman","url":"https://stock-news.laohu8.com/highlight/detail?id=2566536166","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566536166?lang=en_us&edition=fundamental","pubTime":"2025-09-09 07:26","pubTimestamp":1757374008,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250908:nFWN3UV179:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OSL.AU","BK7048","BK7508"],"gpt_icon":0},{"id":"2563094571","title":"BRIEF-Oncosil Medical Reports FY Loss Attributable A$15.1 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2563094571","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563094571?lang=en_us&edition=fundamental","pubTime":"2025-08-29 10:52","pubTimestamp":1756435923,"startTime":"0","endTime":"0","summary":"BRIEF-Oncosil Medical Reports FY Loss Attributable A$15.1 MillionAug 29 (Reuters) - Oncosil Medical Ltd OSL.AX:FY LOSS ATTRIBUTABLE A$15.1 MILLIONFY REVENUES FROM ORDINARY ACTIVITIES A$1.2 MILLIONFurther company coverage: OSL.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250829:nFWN3UK1Y2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OSL.AU","BK7508","BK7048"],"gpt_icon":0},{"id":"2563091265","title":"Oncosil Medical Ltd - FY Revenues From Ordinary Activities a$1.2 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2563091265","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563091265?lang=en_us&edition=fundamental","pubTime":"2025-08-29 10:33","pubTimestamp":1756434826,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250829:nFWN3UK1Y2:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OSL.AU","BK7048","BK7508"],"gpt_icon":0},{"id":"2563091254","title":"Oncosil Medical -  FY Loss Attributable a$15.1 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2563091254","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563091254?lang=en_us&edition=fundamental","pubTime":"2025-08-29 10:33","pubTimestamp":1756434826,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250829:nFWN3UK1Y2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7048","OSL.AU","BK7508"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":17,"code":"91000000","status":"200"}]}}